Eli Lilly (LLY) is likely to raise its full-year revenue outlook as third-quarter sales momentum in its diabetes and weight-loss drugs is expected to offset pricing pressures from the Medicare Bridge ...

Eli Lilly and Company (NYSE:LLY) received a modest price target raise on September 18 from Guggenheim. The brokerage increased its target to $1,284 from $1,273 while maintaining a Buy rating on the ...

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second ...

Eli Lilly (NYSE:LLY) shares rose ~10% in premarket trading on Thursday after the company, with its Q2 2024 financials, increased its full-year outlook above consensus as its weight loss products ...

Pharma's largest company just crossed the 10% threshold in a clinical-stage targeted protein degradation player, the kind of ...

Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing ...

Pharmaceutical giant Eli Lilly is accelerating its growth strategy through significant partnerships and potential acquisitions, prompting a leading investment bank to increase its price target on the ...

Eli Lilly (LLY) and Tractor Supply (TSCO) represent two different dividend investment approaches: the former trades a low ...

Lilly confirmed its fourth-quarter performance and 2025 guidance released in mid-January, with 45% revenue growth and a more than doubling of non-GAAP EPS in the quarter. Management's 2025 guidance ...

The pharmaceutical giant raised its full-year revenue outlook by $3 billion Eli Lilly And Co (NYSE:LLY) surpassed top- and bottom-line expectations for the second quarter, and lifted its full-year ...